- Conditions
- HIV-1
- Interventions
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- Sipuleucel-T, APC-Placebo
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 65
- States / cities
- Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more
- Conditions
- COVID-19 Prevention
- Interventions
- Ad26.COV2.S
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,609 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 31 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy Volunteers
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Pancreatic Cancer
- Interventions
- ARQ-761, Gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Dallas, Texas
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Interventions
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2037
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
- Other · Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio
- Conditions
- Skin Cancer, Metastatic Melanoma
- Interventions
- Fludarabine, Cyclophosphamide, IL-12 transduced TIL
- Drug · Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Crigler-Najjar Syndrome
- Interventions
- AT342
- Genetic
- Lead sponsor
- Audentes Therapeutics
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Strasburg, Pennsylvania
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma
- Interventions
- Cyclophosphamide, CAR-T cell, Fludarabine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thrombocytopenia Related to Chronic Liver Disease
- Interventions
- Avatrombopag, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Advanced Gastrointestinal Stromal Tumor (GIST)
- Interventions
- BGJ398, Imatinib Mesylate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Sonelokimab, Placebo, Adalimumab
- Drug
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Rancho Mirage, California • Duncansville, Pennsylvania
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Interventions
- Rapamycin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 3 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 7
- States / cities
- Loma Linda, California • Hartford, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TAF (Low Dose)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 5
- States / cities
- Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Flu
- Interventions
- the H3N2 M2SR monovalent influenza vaccine, Placebo
- Biological · Other
- Lead sponsor
- FluGen Inc
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- 3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 143
- States / cities
- Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 56 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington